Petros Pharmaceuticals, Inc. (PTPI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5300 |
| Open | 1.5100 |
| Bid | 1.5100 x 2200 |
| Ask | 1.7300 x 800 |
| Day's Range | 1.5000 - 1.5765 |
| 52 Week Range | 0.9170 - 9.5400 |
| Volume | |
| Avg. Volume | 355,841 |
| Market Cap | 3.191M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.2300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PTPI
Related Research
- Petros Pharmaceuticals, Inc.Daily – Vickers Top Insider Picks for 09/21/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat2 days agoArgus Research
ACCESSWIREPetros Pharmaceuticals Provides Letter to Shareholders
Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:
- ACCESSWIRE
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
/ Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.
- ACCESSWIRE
Petros Pharmaceuticals Announces Capital Raise of $15 Million
Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status.
